Clinical Trials Logo

X-Linked Retinitis Pigmentosa clinical trials

View clinical trials related to X-Linked Retinitis Pigmentosa.

Filter by:

NCT ID: NCT06333249 Active, not recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Start date: April 13, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.

NCT ID: NCT06275620 Enrolling by invitation - Clinical trials for X-Linked Retinitis Pigmentosa

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Start date: November 14, 2023
Phase: Phase 2
Study type: Interventional

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.

NCT ID: NCT05926583 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

Start date: September 12, 2023
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).

NCT ID: NCT05874310 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

NCT ID: NCT04926129 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

Natural History of the Progression of X-Linked Retinitis Pigmentosa

XOLARIS
Start date: September 13, 2017
Phase:
Study type: Observational

The objective of the study is to gain a better understanding of disease progression over time in participants with X-linked retinitis pigmentosa (XLRP).

NCT ID: NCT04868916 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa

Start date: July 26, 2021
Phase:
Study type: Observational

The purpose of the study is to identify a cohort of Japanese participants with X-linked retinitis pigmentosa (XLRP) associated with pathogenic variants in the retinitis pigmentosa GTPase regulator (RPGR) gene and to investigate their associated phenotype.

NCT ID: NCT04850118 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Start date: March 14, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.

NCT ID: NCT04794101 Active, not recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Start date: December 4, 2020
Phase: Phase 3
Study type: Interventional

A clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

NCT ID: NCT04671433 Active, not recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Start date: December 4, 2020
Phase: Phase 3
Study type: Interventional

A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

NCT ID: NCT04517149 Active, not recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

Start date: June 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR).